Genmab — Januar 2023
-
This feedback, coupled with positive assessment of Briuvi from KOLs, suggests that TG Therapeutics has a competitive product in its hands, though it simultaneously places further emphasis on the key outstanding question of whether a company of its size and relative commercial experience can maximise this opportunity. KOLs have raised the same issue and speculated that Briuvi could become the subject of a co-marketing agreement or perhaps even trigger a larger company to acquire TG Therapeutics.
-
-
https://investor.seagen.com/events-and-presentations/default.aspx
Seagen JPM presentation -
Norsk finanshus sænker Genmab til "sælg" https://www.proinvestor.com/investornyt/925657/norsk-finanshus-saenker-genmab-til-saelg
-
DARA in refractory autoimmune conditions https://twitter.com/nikolasruffer/status/1612940755194073089
-
https://investors.abbvie.com/static-files/4d7aae8a-65ca-45f9-bc0f-a169b5a7dc9d
AbbVie JPM presentation -
DNB: We expect focus in 2023 to be on epcoritamab’s approval,
launch and initial uptake, but believe consensus is
overestimating the latter while underestimating costs. In
other words, in our view, we are not looking at a Darzalexlike launch curve. We see a risk of the 2023 guidance
disappointing consensus -
DNB: we have cut our target price
DKK2,750 (2,982) and downgraded to SELL (HOLD) -
Den får da godt noget af en lussing. Spændende hvad deres guiding for 2023
siger 22 feb.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind